Ticagrelor

CAS 274693-27-5 35 API suppliersSmall Molecule

Overview

Ticagrelor is an oral antiplatelet agent that belongs to the class of cyclopentyltriazolopyrimidines, used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome or myocardial infarction. It works by reversibly inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.

API suppliers (35)

Suppliers of Ticagrelor evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India19China8Netherlands1Israel1

Country recorded for 29 of 35 suppliers.

18 of 35 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 35 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (36 approved US products), the latest listed US patent on Ticagrelor expires 27 Jul 2036. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

Cardiovascular diseasesThrombosis
Verified Supplier Partner

Do you supply Ticagrelor? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.